Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
Clinical trial NCT02315625 · TERMINATED
Trial details
- NCT number
- NCT02315625
- Sponsor
- National Cancer Institute (NCI)
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-04-08
- Primary completion
- 2019-05-22
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.